These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2811363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ.
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
    Lønning PE, Ekse D.
    J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):409-12. PubMed ID: 8541238
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
    Samojlik E, Santen RJ, Worgul TJ.
    Steroids; 1982 May; 39(5):497-507. PubMed ID: 6293125
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ, Boucher AE, Santner SJ, Henderson IC, Harvey H, Lipton A.
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E, Santen RJ, Kirschner MA, Ertel NH.
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [Abstract] [Full Text] [Related]

  • 16. Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
    Berntsen H, Lønning PE, Ekse D, Netteland B, Johannessen DC, Berge R, Svardal A.
    Cancer Chemother Pharmacol; 1998 Aug; 42(1):46-52. PubMed ID: 9619757
    [Abstract] [Full Text] [Related]

  • 17. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
    Dowsett M, Santner SJ, Santen RJ, Jeffcoate SL, Smith IE.
    Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
    [Abstract] [Full Text] [Related]

  • 18. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J, Haynes B, Ekse D, Dowsett M, Lønning PE.
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
    [Abstract] [Full Text] [Related]

  • 19. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Lønning PE, Haynes BP, Dowsett M.
    Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
    [Abstract] [Full Text] [Related]

  • 20. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M, Harris AL, Smith IE, Jeffcoate SL.
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.